Revive is a clinical-stage company focused on commercializing treatments for Gout and orphan drug indications such as, Cystinuria, Wilson disease and Rett syndrome. Revive’s business model employs a lower risk drug development and commercial strategy by focusing on finding new uses of old drugs through drug repurposing with the objective of finding an appropriate partner or partners to bring the new use drug to the marketplace.
Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 (Bucillamine) in the Treatment of Acute Gout Flares
Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2015
Revive Therapeutics to Present at Marcum MicroCap Conference
Revive Therapeutics Announces Positive Study Results from its Research Collaboration with Rettsyndrome.org
Bruce N. Cronstein, MD, Joins Revive Therapeutics as Medical Advisor